Avinger, Inc. (AVGR)
Company Description
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally.
It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.
In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO.
Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists.
The company was incorporated in 2007 and is headquartered in Redwood City, California.
Country | United States |
Founded | 2007 |
IPO Date | Jan 30, 2015 |
Industry | Medical Instruments & Supplies |
Sector | Healthcare |
Employees | 68 |
CEO | Jeffrey M. Soinski |
Contact Details
Address: 400 Chesapeake Drive Redwood City, California 94063 United States | |
Phone | 650-363-2400 |
Website | avinger.com |
Stock Details
Ticker Symbol | AVGR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001506928 |
CUSIP Number | 053734604 |
ISIN Number | US0537348775 |
Employer ID | 20-8873453 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Jeffrey M. Soinski | President, Chief Executive Officer and Director |
Nabeel P. Subainati | Vice President of Finance, Principal Financial Officer and Accounting Officer |
Himanshu N. Patel | Chief Technology Officer |
Keith Schaefer | Chief Operating Officer |
Corey Gibbs | Vice President of Sales |
Dr. Jaafer Golzar FACC, M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 20, 2024 | 10-K | Annual Report |
Mar 20, 2024 | 8-K | Current Report |
Mar 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Mar 14, 2024 | SCHEDULE 13D | Filing |
Mar 12, 2024 | 8-K | Current Report |
Mar 8, 2024 | 8-K/A | [Amend] Current report |
Mar 7, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 26, 2024 | 8-K | Current Report |
Jan 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |